Swedbank
RARE icon

Swedbank’s Ultragenyx Pharmaceutical RARE Stock Holding History

Swedbank’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,411
Closed -$619K – 721
2023
Q2 		$619K Hold
13,411
– – ﹤0.01% 653
2023
Q1 		$538K Hold
13,411
– – ﹤0.01% 666
2022
Q4 		$621K Hold
13,411
– – ﹤0.01% 660
2022
Q3 		$555K Hold
13,411
– – ﹤0.01% 682
2022
Q2 		$800K Sell
13,411
-24,600
-65% -$1.51M ﹤0.01% 660
2022
Q1 		$2.76M Buy
38,011
+3,111
+9% +$216K 0.01% 598
2021
Q4 		$2.94M Hold
34,900
– – ﹤0.01% 608
2021
Q3 		$3.15M Sell
34,900
-5,300
-13% -$479K 0.01% 599
2021
Q2 		$3.83M Hold
40,200
– – 0.01% 592
2021
Q1 		$4.58M Buy
+40,200
New +$5.47M 0.01% 554

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Swedbank's RARE Position: Q3 2023 in Review

Swedbank sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2023, closing a stake of 13,411 shares — an estimated $619K sold.

Swedbank first reported a position in RARE in Q1 2021 and held it in 10 quarters. The position peaked at $4.58M in Q1 2021. 219 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

  • Swedbank reported no remaining Ultragenyx Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Swedbank sold 13,411 Ultragenyx Pharmaceutical shares in Q3 2023, an estimated $619K.
  • Swedbank first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 10 quarters.
  • Swedbank's Ultragenyx Pharmaceutical position peaked at $4.58M in Q1 2021.
  • 219 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on Swedbank's 13F filing for Q3 2023, filed 6 Dec 2024.